**Highlights of This Issue**  1219

**SPOTLIGHT ON CLINICAL RESPONSE**

1221  
Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent  
Siqing Fu, Aung Naing, Caroline Fu, Macus Tien Kuo, and Razelle Kurzrock

1226  
New Directions for Biologic Targets in Urothelial Carcinoma  
Suzanne Richter and Srikala S. Sridhar

**REVIEW**

1226  
New Directions for Biologic Targets in Urothelial Carcinoma  
Suzanne Richter and Srikala S. Sridhar

**THERAPEUTIC DISCOVERY**

1236  
Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer  
Neil E. Bhola, Maria L. Freillino, Sonali C. Joyce, Malabika Sen, Sufi M. Thomas, Anirban Sahu, Andre Cassell, Ching-Shih Chen, and Jennifer R. Grandis

1247  
IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells  
Giusy Di Conza, Marianna Buttarelli, Olimpia Monti, Marsha Pellegrino, Francesca Mancini, Alfredo Pontecorvi, Katia Scotlandi, and Fabiola Moretti

1257  
Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth  
Christine Helsen, Arnaud Marchand, Patrick Chaltin, Sebastian Munck, Arnout Voet, Annemieke Verstuyf, and Frank Claessens

**PRECLINICAL DEVELOPMENT**

1289  
STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression  
Shinji Kohsaka, Lei Wang, Kazuhiro Yachi, Roshan Mahabir, Takuhito Narita, Tamio Itoh, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, and Shinya Tanaka

1299  
Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions  
Rona Ortenberg, Yair Sapir, Lee Raz, Liat Hershkovitz, Ayelet Ben Arav, Sivao Sapoznik, Iris Barshaek, Camila Avivi, Yackov Berkun, Michal J. Besser, Tehila Ben-Moshe, Jacob Schachter, and Gal Markel

1307  
HDL Mimetics Inhibit Tumor Development in Both Induced and Spontaneous Mouse Models of Colon Cancer  

1317  
Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells  
Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding, Elaine Hsia, Sunita Bhuta, Ryan K. Thor, Robert Damoiseaux, Chaozhuo Liang, and Jiaoti Huang

1320  
Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs  
Ali R. Jazirehi and James S. Economou

1327  
Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications  
Juan Carlos Montero, Xi Chen, Alberto Ocaña, and Atanasio Pandiella
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1353</td>
<td>The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models</td>
<td>Yan Ning, Melissa J. Labonte, Wu Zhang, Pierre O. Bohanes, Armin Gerger, Dongyun Yang, Leonor Benhaim, David Paez, David O. Rosenberg, Kalyan C. Nagulapalli Venkata, Stan G. Louie, Nicos A. Petasis, Robert D. Ladner, and Heinz-Josef Lenz</td>
<td>1365</td>
</tr>
<tr>
<td>1365</td>
<td>Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody</td>
<td>Kelly Davis Orcutt, John J. Rhoden, Benjamin Ruiz-Yi, John V. Frangioni, and K. Dane Wittrup</td>
<td>1373</td>
</tr>
<tr>
<td>1373</td>
<td>Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation</td>
<td>Vlad C. Sandulache, Heath D. Skinner, Yuan Wang, Yunyun Chen, Cristina T. Dodge, Thomas J. Ow, James A. Bankson, Jeffrey N. Myers, and Stephen Y. Lai</td>
<td>1381</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

The CEACAM1 protein protects melanoma cells from cytotoxic lymphocytes in vitro via homophilic intercellular interactions. Immunohistochemistry of a human lymph node infiltrated with melanoma cells for CEACAM1 (brown pigmentation) and CD8 (pink pigmentation) showed that almost all CD8-positive lymphocytes in the tumor and its close vicinity were CEACAM1⁺, while most lymphocytes in other areas distant from tumor edge were mostly CEACAM1⁻. This strongly suggests that CEACAM1-mediated inhibition occurs in vivo and thus its blockade is a promising strategy for cancer immunotherapy. For details, see article by Ortenberg and colleagues on page 1300.
Molecular Cancer Therapeutics

11 (6)


Updated version Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/6

E-mail alerts Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.